Compare AstraZeneca plc (AZN) vs US Bancorp (USB) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

U.S. Bancorp (USB) trades at $62.34, near the lower end of analyst targets, with a modest daily decline. The stock shows bullish technical signals from moving averages and has consistently beaten earnings estimates in recent quarters. Revenue and net income have grown steadily, with 2025 net income reaching $7.57 billion. Recent news highlights new small business payment tools and positive earnings expectations for Q2 2026.

The outlook is supported by strong profitability and a favorable analyst consensus, but risks include elevated debt levels and interest rate sensitivity. The stock offers value with a P/E of 13.07 and a dividend, though net cash flow remains negative. Upside to the $67 consensus target depends on continued earnings execution amid economic uncertainty.